A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

How do you like to unwind at night, before switching off the bedroom lamp and going to sleep? A couple of chapters of a ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

Although it is administered via injection, rather than in pill form, early results show a 200% higher weight loss reduction ...

As GLP-1 drugs like Ozempic soar in popularity for weight loss, this film follows three people on their own GLP-1 journeys and explores how decades of diet culture and society’s relentless pursuit of ...

Novo Nordisk has launched its blockbuster Wegovy weight-loss drug in China, adding the world’s second-largest economy to its ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

NEW YORK (PIX11) — If you’ve noticed ads for weight loss injections flood your social media feeds, you’re not alone. The ...

Many people who diet and lose a significant amount of weight know the devastation of gaining most – or all of it – back ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than ... Novo ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...